Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Blood neoplasia·2026

Same author

Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphoma.

HemaSphere·2026

Same author

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Nature medicine·2026

Same author

Centrifugal microfluidic automation of the protein aggregation capture workflow for robust mass spectrometry-based proteomics.

Lab on a chip·2026

Same author

First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [<sup>68</sup>Ga]Ga-BCY18469 in pancreatic cancer patients: biodistribution, dosimetry and initial findings.

European journal of nuclear medicine and molecular imaging·2026

Same author

Performance evaluation of a CD34 expression assay by digital PCR in bone marrow harvest from healthy donors.

Transfusion·2026

Search research articles

Related Experiment Video

Updated: Sep 17, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

[Trop-2 expression in solid tumors : Expanded protein diagnostics within the molecular tumor board].

Elaine-Pashupati Dopfer^1,2, Matthias Fahrner^1,3, Johanna Thiery^1,3

¹Institut für Klinische Pathologie, Universitätsklinikum Freiburg, Breisacher Str. 115a, 79106, Freiburg, Deutschland.

Pathologie (Heidelberg, Germany)

|June 27, 2025

Summary

Trophoblast surface antigen 2 (Trop-2) expression was evaluated in solid tumors. High Trop-2 expression was found in 46% of cases, supporting its use in personalized cancer therapy recommendations.

Keywords:

Biomarkers Immunoconjugates Off-label use Precision medicine Proteomics

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Sep 17, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

Oncology
Molecular Diagnostics
Biomarker Discovery

Context:

Trophoblast surface antigen 2 (Trop-2) is a target for novel antibody-drug conjugates (ADCs).
Molecular tumor boards (MTBs) integrate multi-omic data for personalized cancer treatment.
Accurate Trop-2 assessment is crucial for guiding ADC therapy.

Purpose:

To systematically evaluate Trop-2 expression in solid tumors using immunohistochemistry (IHC).
To correlate IHC findings with mass spectrometry (MS)-based proteomics data.
To assess the utility of Trop-2 as a biomarker for personalized treatment recommendations within an MTB setting.

Summary:

Trop-2 expression was assessed in 50 solid tumor patients via IHC, categorizing tumors as negative, low, moderate, or high expressing.
High Trop-2 expression was observed in 46% of cases.
Trop-2 IHC scores positively correlated with MS-based protein intensities (r=0.48), validating the IHC method.
Treatment recommendations for Trop-2 ADCs were made in 61% of cases, with 20% considering it the best option.

Impact:

Trop-2 evaluation aids personalized treatment recommendations, especially in off-label settings.
The study validates IHC for Trop-2 assessment and highlights the potential of multi-omics data in biomarker discovery.
Findings support the integration of Trop-2 diagnostics into routine molecular tumor board workflows for optimized cancer care.